S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

Oragenics Stock Forecast, Price & News

-0.02 (-5.71%)
(As of 07/1/2022 02:44 PM ET)
Today's Range
50-Day Range
52-Week Range
3,035 shs
Average Volume
884,428 shs
Market Capitalization
$38.41 million
P/E Ratio
Dividend Yield
Price Target

Oragenics MarketRank™ Forecast

Analyst Rating
Short Interest
2.10% of Float Sold Short
Dividend Strength
News Sentiment
Insider Trading
Acquiring Shares
$26,319 Bought Last Quarter
Proj. Earnings Growth

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

0.41 out of 5 stars

30 days | 90 days | 365 days | Advanced Chart

Receive OGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oragenics and its competitors with MarketBeat's FREE daily newsletter.

Oragenics logo

About Oragenics (NYSEAMERICAN:OGEN) Stock

Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement with Precigen, Inc. and ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.

OGEN Stock News Headlines

Oragenics's Earnings: A Preview - Benzinga
Form 8-K ORAGENICS INC For: Jan 26 - StreetInsider.com
5 Stocks Insiders Are Buying Right Now - InvestorPlace
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Company Calendar

Last Earnings
Fiscal Year End


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$0.11 per share


Free Float
Market Cap
$38.41 million
Not Optionable

Oragenics Frequently Asked Questions

How has Oragenics' stock price performed in 2022?

Oragenics' stock was trading at $0.5237 at the start of the year. Since then, OGEN stock has decreased by 37.0% and is now trading at $0.33.
View the best growth stocks for 2022 here

Are investors shorting Oragenics?

Oragenics saw a increase in short interest in the month of May. As of May 31st, there was short interest totaling 2,790,000 shares, an increase of 34.1% from the May 15th total of 2,080,000 shares. Based on an average trading volume of 651,100 shares, the short-interest ratio is presently 4.3 days. Currently, 2.5% of the company's stock are short sold.
View Oragenics' Short Interest

How were Oragenics' earnings last quarter?

Oragenics, Inc. (NYSEAMERICAN:OGEN) issued its earnings results on Friday, May, 13th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter. The biotechnology company earned $0.02 million during the quarter.
View Oragenics' earnings history

When did Oragenics' stock split? How did Oragenics' stock split work?

Oragenics's stock reverse split before market open on Monday, January 22nd 2018. The 1-10 reverse split was announced on Monday, January 8th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 19th 2018. An investor that had 100 shares of Oragenics stock prior to the reverse split would have 10 shares after the split.

Who are Oragenics' key executives?

Oragenics' management team includes the following people:
  • Dr. Frederick W. Telling Ph.D., Exec. Chairman (Age 70, Pay $213.85k)
  • Mr. Michael O. Sullivan CPA, CFO, Sec., Treasurer & Interim Principal Exec. Officer (Age 66, Pay $315.43k)
  • Dr. Martin Handfield M.Sc., Ph.D., Sr. VP of Discovery Research (Age 51, Pay $255.19k)

What other stocks do shareholders of Oragenics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oragenics investors own include Celsion (CLSN), Jaguar Health (JAGX), Ampio Pharmaceuticals (AMPE), Biocept (BIOC), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Amarin (AMRN), Heat Biologics (HTBX), Idera Pharmaceuticals (IDRA) and Achieve Life Sciences (ACHV).

What is Oragenics' stock symbol?

Oragenics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OGEN."

How do I buy shares of Oragenics?

Shares of OGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Oragenics' stock price today?

One share of OGEN stock can currently be purchased for approximately $0.33.

How much money does Oragenics make?

Oragenics (NYSEAMERICAN:OGEN) has a market capitalization of $38.41 million. The biotechnology company earns $-26,430,000.00 in net income (profit) each year or ($0.17) on an earnings per share basis.

How many employees does Oragenics have?

Oragenics employs 5 workers across the globe.

How can I contact Oragenics?

Oragenics' mailing address is 4902 Eisenhower Blvd Ste 125, TAMPA, FL 33634-6342, United States. The official website for Oragenics is www.oragenics.com. The biotechnology company can be reached via phone at 813 286 7900, via email at johnm@coreir.com, or via fax at 813-286-7904.

This page (NYSEAMERICAN:OGEN) was last updated on 7/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.